Evaluation of relapse-free survival in T3N0 colon cancer: The role of chemotherapy—A multicentric retrospective analysis.

Grande, Roberta; Cosimelli, Maurizio; Gemma, Donatello; Ciancola, F.; Corsi, Domenico; Rossi, Lorena; Sperduti, Isabella; Fabbri, Maria Agnese; Mancini, Raffaello; Ruggeri, Enzo Maria; Zampa, G.; Bianchetti, Sara; Gamucci, Teresa

doi:10.1200/jco.2012.30.4_suppl.578

Cited by 4 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The differences between groups were not statistically significant (p = 0.426). Grande et al 28 found statistically significant differences in favor of the use of chemotherapy in terms of overall survival and of five-year DFS, however Kumar et al 30 found that the use of chemotherapy was associated with worse DFS and DSS.…”

Section: Discussionmentioning

confidence: 97%

Assessment of prognosis in patients with stage II colon cancer

Martins

2015

Journal of Coloproctology

View full text Add to dashboard Cite

j coloproctol (rio j). 2 0 1 5;3 5(4):203-211 w w w . j c o l . o r g . b r Journal of Coloproctology Colon cancer High-and low-risk stage II Disease-free survival Disease-specific survival a b s t r a c t Pathologic staging is currently the most important prognostic factor in colon cancer, although individually this procedure does not provide a complete clinical outcome.This study aimed to determine the disease-specific survival of patients with colon cancer treated in the Braga Hospital from January 2005 to December 2013, according to the American Joint Committee on Cancer, 6th edition, and the disease-free survival and diseasespecific survival of high-and low-risk stage II patients, whether in use, or not, of adjuvant chemotherapy.We obtained a total sample of 578 patients, with 145 and 65 high-and low-risk stage II patients, respectively. We observed a 5-year disease-specific survival rate of 93%, 27.4% and 75% for stage IIA, IIB and IIIA patients, respectively, where IIIA and IIB present statistically significant differences (p = 0.001). In high-risk stage II patients, disease-free survival (p = 0.107) and disease-specific survival (p = 0.037) were higher in the group submitted to chemotherapy. In low-risk patients, disease-free survival was higher in the group submitted to chemotherapy (p = 0.494), while disease-specific survival was lower (p = 0.426).The differences observed between stage IIB and IIIA survival can be explained by the consensual use of adjuvant chemotherapy in stage IIIA, and by its controversial use in stage IIB. Adjuvant chemotherapy showed to be effective only in high-risk stage II patients in terms of disease-specific survival.In the future, other markers, namely molecular ones, may be used to stratify the risk of stage II patients and determine who will benefit from adjuvant chemotherapy. Avaliação o prognóstico de pacientes com cancer de colon no estadio IIPalavras-chave: Câncer de cólon Estadio II de alto risco e baixo risco Sobrevivência livre de doença r e s u m o O estadiamento patológico é, atualmente, o fator de prognóstico mais importante do câncer de cólon, embora individualmente não preveja totalmente o resultado clínico. Neste estudo, pretendeu-se determinar a sobrevivência para uma doença específica (SDE) dos pacientes com câncer de cólon tratados no Hospital de Braga entre janeiro de 2005 e 204 j coloproctol (rio j). 2 0 1 5;3 5(4):203-211 Sobrevivência para uma doença específica dezembro de 2013, de acordo com a 6 a edição da American Joint Committee on Cancer e a Sobrevivência Livre de Doença (SLD) e SDE dos doentes em estadio II, classificados em alto e baixo risco, de acordo com a realização ou não de quimioterapia adjuvante.Obtivemos uma amostra total de 578 pacientes, dos quais uma parcela pertencia ao estadio II de alto ou de baixo risco (145 e 65 pacientes, respetivamente). Observamos SDE a 5 anos de: 93%, 27,4% e 75% para os estadios IIA, IIB e IIIA, respetivamente; IIIA e IIB apresentaram diferenças significativas (p = 0,001). SLD (p = 0,107) e SDE (p = 0,037) pa...

show abstract

Section: Discussionmentioning

confidence: 97%

Assessment of prognosis in patients with stage II colon cancer

Martins

2015

Journal of Coloproctology

View full text Add to dashboard Cite

show abstract

“…It is noteworthy that 5-year overall survival (OS) for all stage II patients was 81%, low-risk stage II patients without adjuvant chemotherapy had a 5-year OS of only 68%, whereas for those receiving it, OS was 86% [20]. One Italian study concentrating solely on pT3N0 reported that adjuvant-treated (AC) patients did much better than did those without it, with no major differences between low-and high-risk (RFS for AC low-risk 87% and high-risk 83%, versus no AC low-risk 75%, high-risk 71%) [21]. As their recurrence rate was markedly higher for those without adjuvant chemotherapy, these authors asked whether all stage II patients should be offered therapy.…”

Section: Most Stage II Patients Should Not Be Offered Adjuvant Chemotmentioning

confidence: 99%

Need for adjuvant chemotherapy after colon cancer surgery – has it decreased?

Böckelman

Glimelius

2017

Acta Oncologica

View full text Add to dashboard Cite

Relevance of Angiogenesis in Neuroendocrine Tumors

Teulé

Martín

Casanovas

2014

Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract

View full text Add to dashboard Cite

While traditional cytotoxic drugs have shown limited efficacy in neuroendocrine tumors (NETs), their biological features have been characterized and can be exploited therapeutically. Their most prominent trait is an extraordinary vascularization in low-grade NETs and an hypoxia-dependent angiogenesis in high-grade NETs, which is associated to a significant expression of many pro-angiogenic molecules. Therefore, several antiangiogenic compounds have been tested in these malignancies and among these, sunitinib has demonstrated activity in pancreatic NET patients by dually targeting the VEGFR and PDGFR pathways. In spite of these efficacious clinical results, apparent resistance to antiangiogenic therapies has been described in NETs animal models and in clinical trials. Therefore, overcoming antiangiogenic resistance is a crucial step in the subsequent development of antiangiogenic therapies. Several strategies have been postulated to fight resistance, but pre-clinical studies and clinical trials will investigate and address these therapeutic approaches in the coming years in order to overcome resistance anti-angiogenic therapies in NETs.

show abstract

Evaluation of relapse-free survival in T3N0 colon cancer: The role of chemotherapy—A multicentric retrospective analysis.

Cited by 4 publications

References 26 publications

Assessment of prognosis in patients with stage II colon cancer

Assessment of prognosis in patients with stage II colon cancer

Need for adjuvant chemotherapy after colon cancer surgery – has it decreased?

Relevance of Angiogenesis in Neuroendocrine Tumors

Contact Info

Product

Resources

About